Representation of OctoPlus N.V. in an exclusive license and product acquisition agreement with co-development partner Biolex Therapeutics

Firm Role: Joint Venture Partner's Counsel

Hughes Hubbard represented Dutch biopharmaceutical company OctoPlus N.V. in an exclusive license and product acquisition agreement with co-development partner Biolex Therapeutics. The agreement covers the development and manufacture of OctoPlus' lead product, Locteron.